🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan flag Japan · Delayed Price · Currency is JPY
2,056.00
-7.00 (-0.34%)
Nov 18, 2026, 3:30 PM JST

Santen Pharmaceutical Balance Sheet

Millions JPY. Fiscal year is Apr - Mar.

Assets

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
81,65780,87592,99794,58257,90383,014
Cash & Short-Term Investments
81,65780,87592,99794,58257,90383,014
Cash Growth
28.47%-13.04%-1.68%63.35%-30.25%32.00%
Accounts Receivable
62,90671,75471,75990,539107,16599,591
Other Receivables
3576324-60-
Receivables
62,94171,83072,08390,539107,22599,591
Inventory
65,43964,58451,59043,18539,35237,141
Other Current Assets
12,64511,4697,6307,8338,8469,680
Total Current Assets
222,682228,758224,300236,139213,326229,426
Property, Plant & Equipment
82,37778,11572,95471,57666,17356,287
Long-Term Investments
34,01033,65826,53933,40042,56040,944
Goodwill
-9,3608,2428,3037,38513,715
Other Intangible Assets
69,56962,29867,22575,51688,924116,502
Long-Term Deferred Tax Assets
9,81210,84310,01710,7652,8103,103
Other Long-Term Assets
-1--1-1
Total Assets
418,450423,033409,277435,699421,179459,976

Liabilities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Accounts Payable
31,69235,35038,98943,53144,94541,185
Accrued Expenses
-8,1806,5147,792--
Short-Term Debt
-3062745424510,936
Current Portion of Leases
-3,2273,0152,6942,8113,029
Current Income Taxes Payable
3,9176,2723,0295,7106,7454,198
Other Current Liabilities
39,37634,53335,01633,01534,75836,473
Total Current Liabilities
74,98587,86886,83792,79689,50495,821
Long-Term Debt
-27,33626,48326,91528,19812,677
Long-Term Leases
-3,8834,4574,9474,9536,290
Pension & Post-Retirement Benefits
1,2281,4241,2211,2921,2711,077
Long-Term Deferred Tax Liabilities
3,7884,3382,6061,3771,5922,526
Other Long-Term Liabilities
35,1182,1672,4923,0022,3654,742
Total Liabilities
115,119127,016124,096130,329127,883123,133

Shareholders' Equity

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Common Stock
8,8468,8248,8068,7778,7028,672
Additional Paid-In Capital
8,9529,5959,7979,8549,7899,370
Retained Earnings
232,735223,285228,291240,029238,071290,477
Treasury Stock
-878-979-1,161-1,018-364-718
Comprehensive Income & Other
54,62956,26440,50948,41337,78129,687
Total Common Equity
304,284296,989286,242306,055293,979337,488
Minority Interest
-953-972-1,061-685-683-645
Shareholders' Equity
303,331296,017285,181305,370293,296336,843
Total Liabilities & Equity
418,450423,033409,277435,699421,179459,976

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Total Debt
-34,75234,22934,61036,20732,932
Net Cash (Debt)
81,65746,12358,76859,97221,69650,082
Net Cash Growth
28.47%-21.52%-2.01%176.42%-56.68%-5.04%
Net Cash Per Share
253.41140.46168.06162.9156.00125.06
Filing Date Shares Outstanding
321.78321.69337.56356.09369.88393.3
Total Common Shares Outstanding
321.78321.68341.36363.21375.54400.27
Working Capital
147,697140,890137,463143,343123,822133,605
Book Value Per Share
945.63923.25838.52842.64782.82843.15
Tangible Book Value
234,715225,331210,775222,236197,670207,271
Tangible Book Value Per Share
729.43700.48617.45611.87526.36517.83